Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy.
ASCO GU 2022: Patients who had disease that failed screening (ie not eligible for the vision trial based on PSMA-PET/CT criteria) had worse outcomes with 177Lu-PSMA treatment. When considering referring patients for 177Lu-PSMA, it is important to consider the imaging inclusion criteria.
